一、临床药理学与治疗学 (2024年第116卷第3期)

September 2024 - Volume 116 - Issue 3 (2024年9月第116卷第3期)
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2024/116/3

Editorial（社论）
1. 精准医疗时代临床药理学的重要作用：剂量的正确选择
Getting the Dosage Right: A Vital Role for Clinical Pharmacology in the Era of Precision Medicine
Iris K. Minichmayr* (Medical University of Vienna, Austria)
Perspective（观点）
Letter to the Editor
2. 口服抗肿瘤药物的治疗药物监测：寻找正确的钉子
Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
Niels A. D. Guchelaar* (Erasmus MC Cancer Institute, The Netherlands)
Reply（回复）
3. 回复：“口服抗肿瘤药物的治疗药物监测：马斯洛的锤子”和“口服抗肿瘤药物的治疗药物监测：寻找正确的钉子”
Reply to: “Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer” and “Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails”
David Combarel,  Paul Gougis* (Gustave Roussy, France; Pitié-Salpêtrière Hospital, AP-HP Sorbonne Université, France)
Commentary（评论）
4. 口服抗肿瘤药物的治疗药物监测：马斯洛的锤子的另一个例子
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
Mark J. Ratain* (The University of Chicago, USA)
Perspective（观点）
5. 药物治疗中剂量优化：因小失大
Optimizing Dosage in Pharmacotherapy—Missing the Forest for the Trees
Susan M. Abdel-Rahman* (Health Data Synthesis Institute, USA)
6. 从剂量到暴露：儿童临床药理学研究和教育范式的转变
From Dose to Exposure: Shifting the Paradigm of Pediatric Clinical Pharmacology Research and Education
Ronaldo Morales Junior* (Cincinnati Children's Hospital Medical Center, USA)
7. 扩展模型指导的药物开发：超越临床试验和监管批准
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
Mohamed A. Kamal* (Regeneron Pharmaceuticals, USA)
8. 正确剂量：美国临床药理学和治疗学精准医疗(TPM)网络的观点
Getting the Dose Right: ASCPT Translational Precision Medicine (TPM) Network Perspectives
Mariam Ahmed* (Takeda Development Center, USA)
9. 精准剂量的最新进展
Recent Advances Addressing the Challenges of Precision Dosing
Iris K. Minichmayr, Thomas M. Polasek* (Medical University of Vienna, Austria; Monash University, Australia)
White Paper（白皮书）
10. 肿瘤药物开发中的剂量优化：国际创新和药品质量开发联盟的白皮书
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
Divya Samineni, Neeraj Gupta (Genentech, Inc., USA; Takeda Development Center Americas, Inc., USA)
11. 超越MABEL：健康与环境科学研究所(HESI)免疫安全技术委员会(ITC)对免疫调节剂首次人体剂量选择的整合方法
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)
Mineo Matsumoto* (Pharmaceuticals and Medical Devices Agency (PMDA), Japan)
Review（综述）
State of the Art Review（艺术状态综述）
12. 基于生理药动学模型的剂量优化：艺术状态和未来
Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future
Karen Rowland Yeo* (Certara UK Limited (Simcyp Division), UK)
13. 剂量优化：开发抗肿瘤药物的监管视角
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
Atiqur Rahman* (US Food and Drug Administration, USA)
Review（综述）
14. 药物-药物-基因相互作用的表型模型，由细胞色素药物代谢酶介导
Phenotypic Models of Drug–Drug-Gene Interactions Mediated by Cytochrome Drug-Metabolizing Enzymes
Roberto Viviani, Julia C. Stingl* (University of Innsbruck, Austria; University Hospital RWTH Aachen, Germany)
15. 超越药物浓度的人群水平目标：精准剂量需要包括优越的药物反应生物标志物的个体水平目标
Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug Responses
Thomas M. Polasek* (Monash University, Australia)
16. “正确剂量”——重新审视主题，重点关注生物制剂
“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents
Diane R. Mould* (Projections Research Inc, USA)
17. 模型指导的强化学习，通过自适应剂量实现精准剂量
Model-Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing
Elena Maria Tosca, Paolo Magni* (University of Pavia, Italy)
18. 双特异性T细胞引导剂在肿瘤学开发中的剂量策略和定量临床药理学
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology
Mohamed Elmeliegy,  Joseph Chen* (Pfizer Inc, USA; Genentech Inc, USA)
Mini Review（微综述）
19. 胃旁路术后及饮食诱导的体重减轻后的口服药物剂量：比我们想象的更简单？从COCKTAIL研究中得到的教训
Oral Drug Dosing After Gastric Bypass and Diet-Induced Weight Loss: Simpler Than We Think? Lessons Learned From the COCKTAIL Study
Kine Eide Kvitne* (University of Oslo, Norway)
Tutorial（教程）
20. 从计划到转变：模型指导的药物开发如何塑造了Zibotentan/Dapagliflozin ZENITH试验的剂量策略
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials
Anne-Kristina Mercier* (R&D, Sweden)
Research（研究）
Brief Report（简报）
21. 持续输注万古霉素的剂量和暴露：一项回顾性研究
Dosing and Exposure of Vancomycin With Continuous Infusion: A Retrospective Study
Judith Y. M. N. Derijks-Engwegen* (Radboudumc, The Netherlands)
Article（文章）
22. 为镰状细胞贫血症儿童的羟基脲模型指导精准剂量的临床决策支持工具HdxSim的合理性、开发和验证
Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia
Alexandra Power-Hays* (Cincinnati Children's Hospital Medical Center, USA)
23. 预测治疗药物监测在癌症口服分子靶向治疗中的临床应用价值的评分
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer
Arthur Géraud, Paul Gougis* (Gustave Roussy, France; Sorbonne Université Médecine, France)
24. 从CEPAM队列中他莫昔芬治疗患者的Z-内酰胺浓度的非线性混合效应模型
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
Anna M. Mc Laughlin, Daniel L. Hertz* (Freie Universitaet Berlin, Germany; University of Michigan College of Pharmacy, USA)
25. 预测治疗性中和肿瘤坏死因子M对人类造血功能的长期影响
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis
Anders Thorsted, Lena E. Friberg* (Uppsala University, Sweden）
26. 评估儿童药物产品的剂量策略
Assessment of Dosing Strategies for Pediatric Drug Products
Zachary L. Taylor, Robert N. Schuck* (Cincinnati Children's Hospital Medical Center, USA; S Food and Drug Administration, USA)
27. 模型指导评估Ritlecitinib在中重度溃疡性结肠炎患者中3期成功的概率
Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis
Jessica Wojciechowski, Arnab Mukherjee* (Pfizer Inc., USA)
28. 儿童受试者中Edoxaban的药代动力学、药效学和安全性：一项I期单剂量研究
Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single-Dose Study
Peng Zou* (Daiichi Sankyo Inc., USA)
29. 急性冠状动脉综合征伴经皮冠状动脉介入治疗的替卡格雷与调整剂量的普拉格雷
Ticagrelor versus Adjusted-Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
Ming-Lung Tsai, Tien-Hsing Chen* (New Taipei Municipal TuCheng Hospital, Taiwan, China; Chang Gung University, Taiwan, China)
30. SARS-CoV-2感染的病毒动力学模型指导药物发现、临床剂量和方案选择
Viral Kinetics Model of SARS-CoV-2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
Allison M. Claas* (Novartis, USA)
31. 转化靶向蛋白降解剂的发现：预测性PK/PD建模的转化力量
Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
Robin Thomas Ulrich Haid,  Andreas Reichel* (Bayer AG, Germany)
32. 评估以患者为中心的样本收集技术，用于大分子和小分子的药代动力学评估
Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules
Sandhya Mandlekar, Saloumeh Fischer* (Genentech, Inc., USA)
33. 利用QSP模型进行MIPD：华法林/INR的案例研究
Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR
Undine Falkenhagen, Wilhelm Huisinga* (PharMetrX Graduate Research Training Program, Germany; University of Potsdam, Germany)
34. 美卓洛尔用于预防心脏或肝脏移植儿童受者器官排斥的批准：监管视角
Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory Perspective
Amer Al-Khouja, Jianmeng Chen* (U.S. Food and Drug Administration, USA)
35. 处理因肝脏代谢变化导致的变异药物暴露：液体活检在肾功能损害中的一个概念验证应用
Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof-of-Concept Application of Liquid Biopsy in Renal Impairment
Amin Rostami-Hodjegan, Brahim Achour* (University of Manchester, UK; The University of Rhode Island, USA)
36. 利用机器学习进行模型指导的精准剂量调整：在一般实践中对左甲状腺素的应用开发、验证和临床模拟试验
Model-Informed Precision Dosing Using Machine Learning for Levothyroxine in General Practice: Development, Validation and Clinical Simulation Trial
Jules M. Janssen Daalen* (Radboud University Medical Center, The Netherlands)
37. 优化癌症免疫疗法的早期临床研究：RG6292的转化之旅，一种新型选择性Treg消耗抗体
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody
Sara Belli,  Maria Amann* (Roche Pharmaceutical Research and Development (pRED), Switzerland)
38. 群体药代动力学和暴露-反应模型，为溃疡性结肠炎患者中Risankizumab剂量选择提供信息
Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
Neha Thakre, Yinuo Pang* (AbbVie Deutschland GmbH & Co. KG, Germany; AbbVie, Inc, USA)
39. 中国老年患者与年龄相关的CYP3A功能变化：基于模型评估氨氯地平的新发现
Aging-Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model-Based Assessment of Amlodipine
Jie En Valerie Sia, Xiaoqiang Xiang* (Fudan University, China)
40. 利用群体药代动力学和暴露-反应分析，为Alnuctamab（一种CD3×BCMA T细胞引导剂）推荐III期剂量提供信息
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis
Brian Kiesel, Allison Gaudy* (Bristol-Myers Squibb, USA)

二、药理学评论

September 2024 - Volume 76 - Issue 5 (2024年9月第76卷第5期)
https://pharmrev.aspetjournals.org/content/76/5

Editorials（社论）
1.《药理学评论》的持久影响——社论
The Enduring Impact of Pharmacological Reviews–Editorial
David R. Sibley
2. 国际基础与临床药理学会。CXVI：NC-IUPHAR和《药理学评论》：30多年的合作——社论
International Union of Basic and Clinical Pharmacology. CXVI: NC-IUPHAR and Pharmacological Reviews: 30+ Years of Collaboration—Editorial
Eliot H. Ohlstein
IUPHAR Nomenclature Report（IUPHAR术语命名报告）
3. 国际基础与临床药理学会CXIV：食欲素受体功能、命名和药理学
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
Jyrki. P. Kukkonen* (University of Helsinki, Finland)
Review Articles（综述文章）
4. 局部应用治疗皮肤病：过去、现在和未来
Topically Applied Therapies for the Treatment of Skin Disease: Past, Present, and Future
Marc Brown* (MLBT Investments and Consultancy, UK)
5. 心血管药物基因组学：从遗传关联的发现到衍生测试的临床采用
Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test
Benoît Delabays, Vincent Mooser* (McGill University, Canada)
6. 针对电压门控钠离子通道的芋螺毒素
Conotoxins Targeting Voltage-Gated Sodium Ion Channels
Shengrong Pei, Xiaopeng Zhu* (Guangxi University, China)
7. 硫化氢及其供体在心血管代谢疾病中的药理学
Pharmacology of Hydrogen Sulfide and Its Donors in Cardiometabolic Diseases
Hai-Jian Sun, Jin-Song Bian* (Jiangnan University, China; Southern University of Science and Technology, China)
8. 寻找正确药物靶标的艺术：新兴方法和策略
The Art of Finding the Right Drug Target: Emerging Methods and Strategies
Zi-Chang Jia, Debatosh Das* (Center for R&D of Fine Chemicals of Guizhou University, China)
9. 大麻素作为美国治疗药物的开发
The Development of Cannabinoids as Therapeutic Agents in the United States
Conor H. Murray* (University of Los Angeles, USA)
10. 肠道屏障、免疫和微生物群：抑郁症犯罪的合作伙伴
Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime
Eva M. Medina-Rodríguez* (Doctor Peset University Hospital, Spain)

三、先进药物输送评论 (2024年第212卷)

September 2024 - Volume 212 (2024年9月第212卷)
https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/212/suppl/C

Editorial（社论）
1. 自身免疫疗法的药物递送技术
Drug delivery technologies for autoimmunity therapies
Ajay S. Thatte, Michael J. Mitchell* (University of Pennsylvania, USA)
Review article（综述文章）
2. 蛋白质和肽药物的亚细胞靶向策略
Subcellular targeting strategies for protein and peptide delivery
Hao Su* (Sichuan University, China)
3. 细胞外囊泡的细胞内旅程及其在生物医学中的应用
Unignored intracellular journey and biomedical applications of extracellular vesicles
Jiuhong Zhao, Peng Zhang* (Shenyang Pharmaceutical University, China)
4. 选择性地将成像探针和治疗剂递送到内质网或高尔基体：当前策略及未来展望
Selective delivery of imaging probes and therapeutics to the endoplasmic reticulum or Golgi apparatus: Current strategies and beyond
Hana Cho, Han Chang Kang* (The Catholic University of Korea, Republic of Korea)
5. 针对与细胞器相关疾病的精确亚细胞靶向方法
Precise subcellular targeting approaches for organelle-related disorders
Gayong Shim, Yu Seok Youn* (Soongsil University, Republic of Korea; Sungkyunkwan University, Republic of Korea)
6. 基于水凝胶的方法针对自身免疫疾病的超敏机制
Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease
Kenneth M. Kim, Christopher B. Rodell* (Drexel University College of Medicine, USA)
7. 内在无序蛋白聚合物的可编程性和生物医学应用
Programmability and biomedical utility of intrinsically-disordered protein polymers
Maria Camila Giraldo-Castaño, Felipe Garcia Quiroz* (Georgia Institute of Technology and Emory University, USA; Emory University, USA)
8. 光在评估组织中分子扩散中的作用：病理学的区分
Light in evaluation of molecular diffusion in tissues: Discrimination of pathologies
Luís R. Oliveira, Luís M. Oliveira* (Polytechnic of Porto – School of Health (ESS), Portugal; Technology and Science (INESC TEC), Portugal)

四、药理学发展趋势 (2024年第45卷第9期)

September 2024 - Volume 45 - Issue 9 (2024年9月第45卷第9期)
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(23)X0010-8

Spotlight（聚焦）
1. “活药”靶向CD70治疗晚期肾肿瘤
'Living drugs' target CD70 in advanced renal tumors
Kilian Wagner,Peter J. Siska* (University Hospital Regensburg, Germany)
Forum（论坛）
2. 结构揭示SGLT抑制剂的作用机制
Structures reveal how SGLT inhibitors work
Zejian Sun, Lei Chen* (Peking University, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, China)
3. 针对自闭症治疗的表观遗传酶
Targeting epigenetic enzymes for autism treatment
Zhen Yan* (State University of New York at Buffalo, USA)
Opinion（观点）
4. 自身免疫性神经病及其它领域的表位格局
Epitope landscape in autoimmune neurological disease and beyond
Ivan Talucci, Hans M. Maric* (University of Würzburg, Germany)
Reviews（综述）
5. 人乳头瘤病毒相关癌症的纳米治疗：突破与挑战
Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges
Jéssica Lopes-Nunes, Carla Cruz* (University of Beira Interior, Portugal)
6. 1型糖尿病中低氧诱导因子1的作用
Role of hypoxia-inducible factor 1 in type 1 diabetes
Raphael R. Fagundes, Cormac T. Taylor* (Leiden University Medical Center, The Netherlands; University College Dublin, Ireland)
7. STAT3途径的靶向与STAT3降解剂
Targeting the STAT3 pathway with STAT3 degraders
Zhijie Wang, Jianjun Chen* (Shenzhen Hospital, Southern Medical University, China; Southern Medical University, China)
8. 肠道微生物代谢物的新兴化学生理多样性
Emerging chemophysiological diversity of gut microbiota metabolites
Xiaorong Lin, Xiaohui Zhao* (Zhejiang University, China)
9. 自身免疫性疾病CAR-T细胞治疗的前沿
Frontiers in CAR-T cell therapy for autoimmune diseases
Yan-Ruide Li* (University of California, USA)

五、药理学与治疗学 (2024年第261卷)

September 2024 - Volume 261 (2024年9月第261卷)
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/261/suppl/C

Review article（综述文章）
1. 动脉粥样硬化中斑块内新生血管的药理干预
Pharmacological interventions for intraplaque neovascularization in atherosclerosis
Azizah Ugusman* (Universiti Kebangsaan Malaysia, Malaysia)
2. 泌尿道感染中抗生素耐药性上升的预防和治疗现状与新展望
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections
Emina K. Sher* (Nottingham Trent University, UK)
3. 克服癌症药物抗性需要针对异常选择性剪接的新策略
Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing
Ji Zhang, Jianguo Feng* (The Affiliated Hospital, Southwest Medical University, China)
4. 维生素和脂肪酸对抗化疗引起的肠道粘膜炎
Vitamins and fatty acids against chemotherapy-induced intestinal mucositis
Alexandra Alcorta, Raquel Abalo* (University Rey Juan Carlos (URJC), Spain)

六、药物 (2024年第84卷第9期)

September 2024 - Volume 84 - Issue 9 (2024年9月第84卷第9期)
https://link.springer.com/journal/40265/volumes-and-issues/84-9

Current Opinion（当前观点）
1. 对传统抗风湿药物反应不足的类风湿关节炎患者使用生物制剂或Janus激酶抑制剂
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Ennio Giulio Favalli, Gabriella Maioli* (Università degli Studi di Milano, Italy)
Leading Article（重点文章）
2. 预防高危个体的类风湿关节炎：当前状况与未来展望
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
Task Toyoda, Kulveer Mankia* (University of Leeds, UK)
Review Article（综述文章）
3. 神经性吞咽障碍的新疗法和进展
New and Evolving Treatments for Neurologic Dysphagia
Ayodele Sasegbon, Shaheen Hamdy* (University of Manchester, UK)
4. 肥胖症的药物治疗作为减肥手术的辅助手段
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Luděk Horváth, Martin Haluzík* (Institute for Clinical and Experimental Medicine, Czech Republic)
Systematic Review（系统综述）
5. 复方对乙酰氨基酚治疗背痛和骨关节炎：系统综述和Meta分析
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Zhiying Cao, Stephanie Mathieson* (The University of Sydney, Australia)
AdisInsight Report（AdisInsight报告）
6. Mavorixafor：首次批准
Mavorixafor: First Approval
Sheridan M. Hoy
7. Zolbetuximab：首次批准
Zolbetuximab: First Approval
Susan J. Keam
8. Tovorafenib：首次批准
Tovorafenib: First Approval
Sohita Dhillon
9. Tarlatamab：首次批准
Tarlatamab: First Approval
Sohita Dhillon
10. Tunlametinib：首次批准
Tunlametinib: First Approval
Susan J. Keam

七、药理学研究 (2024年第207卷)

September 2024 - Volume 207 (2024年9月第207卷)
https://www.sciencedirect.com/journal/pharmacological-research/vol/207/suppl/C

Review Articles（综述文章）
1. 心灵超越物质：迷幻药和肠-脑轴的微生物心智景观
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Giorgia Caspani* (University of British Columbia, Canada)
2. IUPHAR综述——胰高血糖素样肽-1 (GLP-1) 与物质使用障碍：一个新兴的药物治疗靶点
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns VI, Elizabeth H. Tressler, Lorenzo Leggio*, Mehdi Farokhnia* (National Institutes of Health, USA)
3. 氨基酸代谢改变在急性缺血性卒中中的作用：从机制到应用
The role of amino acid metabolism alterations in acute ischemic stroke: From mechanism to application
Xiang-Ping Wang, Sheng Chen* (The Second Affiliated Hospital of Zhejiang University School of Medicine, China; First People's Hospital of Xiaoshan District, China)
4. RNA甲基化遗传和表观遗传机制在心肌病治疗中的影响
Unravelling the impact of RNA methylation genetic and epigenetic machinery in the treatment of cardiomyopathy
Li Liu, Jianjun Huang* (Affiliated Hospital of Youjiang Medical University for Nationalities, Youjiang Medical University for Nationalities, China; Youjiang Medical University for Nationalities, Affiliated Hospital of Youjiang Medical University for Nationalities, China)
5. 天然多糖作为治疗各种肾脏损伤的有前景的肾脏保护剂
Natural polysaccharides as promising reno-protective agents for the treatment of various kidney injury
Yufei Ye, Chengjian Zheng* (Second Military Medical University/Naval Medical University, China)
6. 宿主-肠道微生物代谢相互作用及其在胃肠癌的精准诊断和治疗中的作用
Host-Gut Microbiota Metabolic Interactions and Their Role in Precision Diagnosis and Treatment of Gastrointestinal Cancers
Chunhao Cao, Chao Liang* (Southern University of Science and Technology, China)
7. “发炎”的抑郁：抑郁和炎症之间的相互作用以及当前抗炎策略用于抑郁的综述
“Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression
Yishu Yin, Weihong Lu* (Harbin Institute of Technology, China)
8. 多酚在调节线粒体自噬中的作用：治疗干预的启示
The role of polyphenols in modulating mitophagy: Implications for therapeutic interventions
Xinyu Lin, Jinlian Wang* (Chengdu University of Traditional Chinese Medicine, China; Traditional Chinese Medicine Hospital of Meishan, China)
9. 内皮细胞源性细胞外囊泡在心血管疾病中的见解：分子机制和临床意义
Insight into endothelial cell-derived extracellular vesicles in cardiovascular disease: Molecular mechanisms and clinical implications
Xia Wang, Ben He* (Shanghai Chest Hospital, Shanghai Jiao Tong University, China)
10. 非核苷类DNMT1和DNMT3抑制剂用于靶向癌症治疗
Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy
Ting Chen, Stéphanie Desbène-Finck* (Université Paris cité, France)
11. 与血管疾病相关的微生物群改变：后生元作为肠道-血管轴的下一代神奇子弹
Microbiota alterations associated with vascular diseases: postbiotics as a next-generation magic bullet for gut-vascular axis
Lorenzo Flori* (University of Pisa, Italy)
12. 内质网应激对肝脏疾病代谢酶的调控机制
Regulation mechanism of endoplasmic reticulum stress on metabolic enzymes in liver diseases
Shaojun Zhou, Lushan Yu* (Zhejiang University, China)
13. KLF4与炎症性疾病的调节机制综述：当前状态和未来展望
A review of KLF4 and inflammatory disease: Current status and future perspective
Yidan Liang, Lin Xu* (Zunyi Medical University, China)
14. 用于癌症治疗的共轭药物结构中的天然源载荷：最新进展和未来方向
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions
Cuiping Li, Wei Fan* (Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China)
Regular Articles（常规文章）
15. 环状Tachyplesin I杀死增殖、非增殖和耐药性黑色素瘤细胞而不诱导耐药性
Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance
Aurélie H. Benfield, Sónia Troeira Henriques* (Queensland University of Technology, Australia)
16. 铁氧化物(Fe₃O₄)纳米粒子药物在现实胆管癌模型中的分布设计及其在磁感应热疗中温度升高的模拟
Design of the distribution of iron oxide (Fe₃O₄) nano-particle drug in realistic cholangiocarcinoma model and the simulation of temperature increase during magnetic induction hyperthermia
Yawen Lu, Wenbo Meng* (The First Clinical Medical College of Lanzhou University, China; The First Hospital of Lanzhou University, China)
17. G-蛋白途径抑制因子2 (GPS2) 通过抑制K63泛素化调节线粒体相关翻译
Inhibition of K63 ubiquitination by G-Protein pathway suppressor 2 (GPS2) regulates mitochondria-associated translation
Yuan Gao, Valentina Perissi* (Boston University, USA)
18. BET蛋白抑制剂Apabetalone通过调节P300/H3K27ac/PLK1轴预防焦亡来抑制糖尿病中的肾脏损伤
Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis
Min Wang, QiuLing Fan* (First Hospital of China Medical University, China)
19. 预测TGF-β抑制剂在重新敏感化疗（放疗）食管腺癌中的反应的生物标志物
Predictive biomarkers for response to TGF- β inhibition in resensitizing chemo(radiated) esophageal adenocarcinoma
Dajia Liu, Maarten F. Bijlsma* (Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, the Netherlands)
20. 通过外泌体、肠道微生物和代谢组学分析，年轻供体小鼠粪便微生物移植在自然衰老过程中的脑保护机制
The brain-protective mechanism of fecal microbiota transplantation from young donor mice in the natural aging process via exosome, gut microbiota, and metabolomics analyses
Longfei Lin, Hongjun Yang* (China Academy of Chinese Medical Sciences, China)
21. 汉防己甲素激活STING/TBK1/IRF3途径以增强非小细胞肺癌中抗PD-1免疫治疗的疗效
Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer
Yan Tan, Dan Li* (Sun Yat-sen University, China)
22. 沉默肌动蛋白抑制急性髓系白血病细胞增殖和肿瘤生长，通过提高核转运蛋白α2介导的自噬
Silencing of tropomodulin 1 inhibits acute myeloid leukemia cell proliferation and tumor growth by elevating karyopherin alpha 2–mediated autophagy
Yuan Xia, Defang Li* (Binzhou Medical University, China)
23. Ebronucimab在中国高胆固醇血症患者中的应用——一项随机双盲安慰剂对照的3期试验，评估Ebronucimab的疗效和安全性
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
Yanyan Zhang, Bo Zheng* (Peking University First Hospital, China)
24. CD31在类风湿关节炎自噬途径中的代谢调控作用
CD31 orchestrates metabolic regulation in autophagy pathways of rheumatoid arthritis
Kenneth CP Cheung* (Hong Kong Baptist University School of Chinese Medicine, Hong Kong, China)

八、抗病毒研究 (2024年第229卷)

September 2024 - Volume 229 (2024年9月第229卷)
https://www.sciencedirect.com/journal/antiviral-research/vol/229/suppl/C

Short communication（短篇通讯）
1. LHF-535和法匹拉韦联合给药可预防实验性的胡宁病毒（Junín virus）感染和疾病
Coadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease
Jonna B. Westover, Brian B. Gowen* (Utah State University, USA)
Research article（研究文章）
2. 新出现的禽流感A病毒对神经氨酸酶和帽依赖性内切核酸酶抑制剂的基因型和表型敏感性
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors
Konstantin Andreev, Elena A. Govorkova* (St. Jude Children's Research Hospital, USA)
3. 高通量分析鉴定出A(H1N1)pdm09流感病毒中PA-L106R氨基酸替换，该替换在体外降低了对Baloxavir的敏感性
High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro
Dongdong Chen, Wen Su, Hui-Ling Yen* (The University of Hong Kong, Hong Kong SAR, China)
Review article（综述文章）
4. 直接作用抗病毒药物治疗RSV的综述
Direct-acting antivirals for RSV treatment, a review
Brecht Bonneux, Peter Delputte* (University of Antwerp, Belgium)
Research article（研究文章）
5. HIV-1 gp120多态体对temsavir抑制的敏感性与temsavir结合速率相关
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate
David Wensel* (ViiV Healthcare, USA)
6. 通过Alum:CpG复合佐剂增强COVID-19疫苗的免疫反应
Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant
Jia Ji, Hangping Yao* (The First Affiliated Hospital, Zhejiang University, China)
7. 在日本2022-2023年流感季节期间，检测到在Baloxavir marboxil治疗前后具有聚合酶酸性亚基替换的流感A(H3N2)病毒
Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan
Irina Chon* (Niigata University, Japan)
8. 在3期SCORPIO-SR试验中，早期使用Ensitrelvir治疗预防后COVID-19症状
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Hiroshi Yotsuyanagi, Takeki Uehara* (The University of Tokyo, Japan; Shionogi & Co., Ltd., Japan)
9. ACE2的模拟肽可保护免受SARS-CoV-2感染，并减少与COVID-19相关的肺部炎症
A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19
Ernna H. Oliveira, Geraldo A. Passos* (University of São Paulo (USP), Brazil)
10. 携带三个呼吸合胞病毒（RSV）融合糖蛋白表位位点重复序列的冷适应流感疫苗可保护BALB/c小鼠和棉鼠免受RSV感染
Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection
Yongru Xu, Penghui Yang* (The First Medical Center of Chinese PLA General Hospital, China)
11. Molnupiravir的代谢产物β-d-N4-羟基胞嘧啶在体外对狂犬病病毒表现出抗病毒活性
β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus
Kei Konishi, Akihiko Sato* (Shionogi & Co., Ltd., Japan)
Review article（综述文章）
12. 通过双特异性抗体、T细胞引导抗体桥接感染和免疫效应细胞激活适应性免疫是慢性乙型肝炎治疗的有前景的新疗法
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B
Zhe Xie, Ulrike Protzer* (Technical University of Munich / Helmholtz Munich, Germany)

九、英国药理学杂志 (2024年第181卷第17-18期)

（一）September 2024 - Volume 181 - Issue 17 (2024年9月第181卷第17期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/17

EDITORIAL（社论）
1. 2000年至2023年间《英国药理学杂志》文章撤稿的洞见：减少含有欺诈内容文章的影响
Insight in article retractions in British Journal of Pharmacology between the years 2000–2023. Implications for reducing fraud-containing articles
Marcel A. G. van der Heyden* (University Medical Center Utrecht, The Netherlands)
REVIEW ARTICLE（综述文章）
2. β-arrestin2调控机制的洞见及其在疾病中的新兴作用
Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases
Meng Qi, Wu-Yi Sun* (Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anhui-inflammatory and Immune Medicine, China)
RESEARCH ARTICLE（研究文章）
3. AdipoRon通过核GAPDH诱导的sirtuin 1激活增强自噬促进阿尔茨海默病中淀粉样β的清除
AdipoRon promotes amyloid-β clearance through enhancing autophagy via nuclear GAPDH-induced sirtuin 1 activation in Alzheimer's disease
Fengjiao Sun, Haijing Yan* (Binzhou Medical University Hospital, China)
4. 纹状体中M4毒蕈碱受体的激活减少两个不同的图雷特综合征小鼠模型的抽动样行为
Activation of M4 muscarinic receptors in the striatum reduces tic-like behaviours in two distinct murine models of Tourette syndrome
Roberto Cadeddu, Marco Bortolato* (University of Utah, USA)
5. 通过上调神经元BDNF-TrkB信号通路，电子烟中的尼古丁吸入促进创伤性脑损伤后感觉运动功能的恢复
Nicotine inhalant via E-cigarette facilitates sensorimotor function recovery by upregulating neuronal BDNF–TrkB signalling in traumatic brain injury
Dongsheng Wang, Brian P. Head* (VA San Diego Healthcare System, USA)
6. HIF-1α和适配蛋白LIM及衰老细胞抗原样结构域蛋白1轴通过与波形蛋白相互作用促进血管紧张素II诱导的高血压中的肾小管间质纤维化
HIF-1α and adaptor protein LIM and senescent cell antigen-like domains protein 1 axis promotes tubulointerstitial fibrosis by interacting with vimentin in angiotensin II-induced hypertension
Wei-Jie Ni, Bin Wang* (Zhong Da Hospital, Southeast University School of Medicine,  China)
7. STING的药理抑制减少创伤性脑损伤后神经炎症介导的损伤
Pharmacological inhibition of STING reduces neuroinflammation-mediated damage post-traumatic brain injury
Amelia L. Fryer, Peter J. Crack* (University of Melbourne, Australia)
8. 柚皮素通过抑制降钙素基因相关肽信号减轻紫杉醇诱导的疼痛，并增强紫杉醇的抗肿瘤作用
Naringenin relieves paclitaxel-induced pain by suppressing calcitonin gene-related peptide signalling and enhances the anti-tumour action of paclitaxel
Chen Pan, Xiaowei Chen* ( Ningbo University, China)
9. ST-2560，一种选择性的NaV1.7钠通道抑制剂，影响非人灵长类动物的防御反应和心血管反射
ST-2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non-human primates
John V. Mulcahy* (SiteOne Therapeutics, Inc., USA)
10. 神经保护性淀粉样β N端肽不同地改变人类α7-和α7β2-烟碱型乙酰胆碱（nACh）受体单通道特性
Neuroprotective amyloid β N-terminal peptides differentially alter human α7- and α7β2-nicotinic acetylcholine (nACh) receptor single-channel properties
Catherine F. Roberts, Andrew A. George* (University of Bath, UK; Virginia Commonwealth University, USA)
11. 离子通道TRPM8是免疫抑制剂雷帕霉素在初级感觉神经元中的直接靶标
The ion channel TRPM8 is a direct target of the immunosuppressant rapamycin in primary sensory neurons
José Miguel Arcas, Félix Viana* (Universidad Miguel Hernández-CSIC, Spain)
12. 尼可地尔通过调节关键信号通路SIRT1/PGC-1α/TFAM、JAK1/STAT3和miRNA-132表达减轻三氧化二砷诱导的肺损伤
Nicorandil mitigates arsenic trioxide-induced lung injury via modulating vital signalling pathways SIRT1/PGC-1α/TFAM, JAK1/STAT3, and miRNA-132 expression
Basel A. Abdel-Wahab, Ehab A. M. El-Shoura* (Najran University, Saudi Arabia; Al-Azhar University, Egypt)
13. 抗胰蛋白酶样1抗体通过抑制依赖于STAT3的CXCL8表达减轻特应性皮炎样皮肤炎症
Anti-chitinase-3-like 1 antibody attenuated atopic dermatitis-like skin inflammation through inhibition of STAT3-dependent CXCL8 expression
Ji Eun Yu, Jin Tae Hong* (Chungbuk National University, Republic of Korea)
14. TRPA1上调介导体外牙髓炎模型中的氧化应激
TRPA1 up-regulation mediates oxidative stress in a pulpitis model in vitro
Árpád Kunka, Balázs István Tóth* (University of Debrecen, Hungary)
15. ApTOLL：一种新的治疗性寡核苷酸，用于多发性硬化后的细胞保护和(再)髓鞘化
ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis
Beatriz Fernández-Gómez, Fernando de Castro* (Instituto Cajal—CSIC, Spain)
16. 局部应用P2X2/P2X3嘌呤受体抑制剂抑制药物的苦味和其他味觉品质
Topical application of a P2X2/P2X3 purine receptor inhibitor suppresses the bitter taste of medicines and other taste qualities
Linda J. Flammer, Michael G. Tordoff* (Monell Chemical Senses Center, USA)

（二）September 2024 - Volume 181 - Issue 18  (2024年9月第181卷第18期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/18

RESEARCH ARTICLE（研究文章）
1. Montelukast通过抵消SOD1G93A雌性小鼠中的少突胶质细胞功能障碍和异常的胶质细胞反应性改善疾病结果
Montelukast improves disease outcome in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity
Stefano Raffaele, Marta Fumagalli* (Università degli Studi di Milano, Italy)
2. 突变的细胞质脆性X信使核糖核蛋白1 (FMR1) 相互作用蛋白2 (CYFIP2 S968F) 调节可卡因诱导的奖赏行为和伏隔核的可塑性
The mutated cytoplasmic fragile X messenger ribonucleoprotein 1 (FMR1)-interacting protein 2 (CYFIP2 S968F) regulates cocaine-induced reward behaviour and plasticity in the nucleus accumbens
Young-Jung Kim, Choon-Gon Jang* (Sungkyunkwan University, Republic of Korea)
3. 人参皂苷Rh4作为新型AMPK激活剂预防内皮功能障碍
Ginsenoside Rh4 prevents endothelial dysfunction as a novel AMPK activator
Jiawei Zhang, Jiankang Liu* (Xi'an Jiaotong University, China)
4. 蛋白酶激活受体PAR4拮抗剂ML354对实验性中风小鼠的直接神经保护作用
Direct neuronal protection by the protease-activated receptor PAR4 antagonist ML354 after experimental stroke in mice
Michael Fleischer* (University Hospital Essen, Germany)
5. 在心脏心室肌膜中识别和表征含有Kir6.1的ATP敏感性钾通道的功能
Identification and characterisation of functional Kir6.1-containing ATP-sensitive potassium channels in the cardiac ventricular sarcolemmal membrane
Sean Brennan, Richard D. Rainbow* (University of Liverpool, UK)
6. 一种新型的ryanodine受体2抑制剂M201-A增强钠尿、肾功能和lusi-inotropic作用：临床前和I期研究
A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study
Noboru Kaneko* (Dokkyo Medical University, Japan)
7. 肠道微生物群对一线抗高血压药物引起的血压降低效应的不同贡献
Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs
Cristina González-Correa, Iñaki Robles-Vera* (University of Granada, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain)
8. 施万细胞TRPA1引发利血平诱导的小鼠纤维肌痛痛感
Schwann cell TRPA1 elicits reserpine-induced fibromyalgia pain in mice
Evelyne Silva Brum, Romina Nassini* (Federal University of Santa Maria, Brazil; University of Florence, Italy)
9. α-吡咯烷基丁硫基噻吩，一种新的合成卡西酮，在啮齿动物中的神经药理学特性；多巴胺系统的作用
The neuropharmacological properties of α-pyrrolidinobutiothiophenone, a new synthetic cathinone, in rodents; role of the dopaminergic system
Oc-Hee Kim, Eun Young Jang* (Korea Institute of Toxicology, Republic of Korea)
10. 七氟醚通过抑制含有GluN2D的NMDA受体在神经元上的表达发挥抗抑郁作用
Sevoflurane acts as an antidepressant by suppression of GluN2D-containing NMDA receptors on interneurons
Fei Guo, Zhiqiang Liu* (Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, China)
11. 线粒体钙单向转运体抑制剂Ru265通过非靶向效应增加神经元兴奋性并减少神经传递
The mitochondrial calcium uniporter inhibitor Ru265 increases neuronal excitability and reduces neurotransmission via off-target effects
Peng Xu, Robert B. Renden* (University of Nevada, USA)
12. 皮下给药一种新型TRPM8拮抗剂逆转冷过敏，同时减轻核心体温下降
Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature
Michael S. Gold, V. Blair Journigan* (University of Pittsburgh, USA)

十、临床药代动力学 (2024年第63卷第9期)

September 2024 -Volume 63 - Issue 9 (2024年9月第63卷第9期)
https://link.springer.com/journal/40262/volumes-and-issues/63-9

Review Article（综述文章）
1. 机器学习方法在抗癌药物精准剂量治疗中的应用：范围综述
Machine Learning Methods for Precision Dosing in Anticancer Drug Therapy: A Scoping Review
Olga Teplytska, Ulrich Jaehde* (University of Bonn, Germany)
2. 虚拟药物研究在新药研究与开发中的应用：挑战与机遇
Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity
Xiuqi Li, Hongyun Wang* (Peking Union Medical College Hospital, China)
Systematic Review（系统综述）
3. 系统性皮质类固醇在自身免疫和炎症性疾病中的药代动力学和药效学：当前证据综述
Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence
Julia E. Möhlmann* (University Utrecht, The Netherlands)
Original Research Article（原创研究文章）
4. 达巴万星和C反应蛋白在金黄色葡萄球菌性骨关节感染患者中的群体药代动力学和药效学
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections
Pier Giorgio Cojutti* (University of Bologna, Italy)
5. 研究非霍奇金淋巴瘤患者中Axicabtagene Ciloleucel (axi-cel) 动力学的影响因素
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma
Magali Chartier* (Certara North America, USA)
6. 费城染色体阳性慢性髓性白血病患者使用Asciminib的剂量论证，无论是否存在T315I突变
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation
Francois Pierre Combes* (Novartis Pharmaceuticals Corporation, USA)
7. 将贝利木单抗的疗效和药代动力学外推以支持其在儿童狼疮性肾炎中的应用
Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis
Richard Dimelow* (GSK, UK)
8. 慢性肾脏病贫血患者达普司他群体药代动力学的整合
Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia
Kelly M. Mahar* (GSK, USA)
9. 在体外生命支持下接受阿那曲生的危重病儿童的生理基础药代动力学建模
Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support
Samuel Dubinsky, Andrea Edginton* (University of Waterloo, Canada)
10. 开发并应用成人和青少年人群中Elagolix的生理基础药代动力学模型
Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population
Xinghai Zhang, Qing Wen* (Central Hospital Affiliated to Shandong First Medical University, China)